These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 28210841

  • 1. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
    Alfakeeh K, Azar M, Alfadhel M, Abdullah AM, Aloudah N, Alsaad KO.
    Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Noris M, Bresin E, Mele C, Remuzzi G.
    ; 1993 May. PubMed ID: 20301541
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome.
    Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M.
    Pediatr Nephrol; 2010 May 07; 25(5):947-51. PubMed ID: 20108004
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
    Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.
    Blood; 2014 Sep 11; 124(11):1715-26. PubMed ID: 25037630
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
    Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.
    Rev Med Interne; 2011 Apr 11; 32(4):232-40. PubMed ID: 21376430
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anti-complement therapy for glomerular diseases.
    Bomback AS.
    Adv Chronic Kidney Dis; 2014 Mar 11; 21(2):152-8. PubMed ID: 24602464
    [Abstract] [Full Text] [Related]

  • 18. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
    Békássy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-Bacchi V, Karpman D.
    Nephrol Dial Transplant; 2013 Nov 11; 28(11):2899-907. PubMed ID: 24009284
    [Abstract] [Full Text] [Related]

  • 19. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
    Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.
    Pediatrics; 2014 Jun 11; 133(6):e1769-71. PubMed ID: 24843058
    [Abstract] [Full Text] [Related]

  • 20. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome.
    Funato M, Uemura O, Ushijima K, Ohnishi H, Orii K, Kato Z, Yamakawa S, Nagai T, Ohara O, Kaneko H, Kondo N.
    J Clin Immunol; 2014 Aug 11; 34(6):691-5. PubMed ID: 24906628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.